Preclinical News and Research

RSS

Imec and PEIRA develop platform for in-vitro study of brain tissue

The nanoelectronics research centre imec and Peira, a Belgium-based manufacturer of pharmaceutical and chemical research instruments, jointly developed an innovative slice-tilting instrument for in-vitro research on brain tissue. The new tool enables long-term studying of brain cultures through electronic stimulation and read-out, essential in getting insight into the functioning of the brain.

17 Nov 2010

Aeterna Zentaris presents results of orally active compounds with anti-tumor effects at EORTC-NCI-AACR Symposium

Aeterna Zentaris Inc. today presented posters on encouraging preclinical results for AEZS-129 and AEZS-132, two novel orally active compounds with anti-tumor effects.

17 Nov 2010

New slice-tilting instrument for in-vitro research on brain tissue

17 Nov 2010

Infinity announces enrollment in IPI-926 Phase 1b/2 clinical trial for pancreatic cancer

Infinity Pharmaceuticals, Inc. today announced that enrollment is ongoing locally for a Phase 1b/2 clinical trial of IPI-926, Infinity's oral molecule that inhibits Smoothened, a key component of the Hedgehog pathway, in combination with Gemzar (gemcitabine) in patients with previously untreated, metastatic pancreatic cancer.

17 Nov 2010

Alkermes's ALKS 33 drug candidate offers potential treatment for multiple disease indications

Alkermes, Inc. today announced the presentation of promising preclinical results for its proprietary opioid modulator, ALKS 33, showing the drug candidate's potential in multiple disease indications.

17 Nov 2010

Enzon presents data on three investigational mRNA antagonists at EORTC-NCI-AACR Symposium

Enzon Pharmaceuticals, Inc. today presented data from preclinical studies of three investigational messenger RNA (mRNA) antagonists. These antagonists are based on the locked nucleic acid (LNA) technology platform targets licensed from Santaris Pharma A/S.

17 Nov 2010

MRL announces acquisition of world's largest cryo-preserved human cancer tissue bank

Molecular Response (MRL), a privately held molecular diagnostic services company and a leader in the identification of target populations for high value therapeutics, announced today the acquisition of the world's largest cryo-preserved human cancer tissue bank—more than 144,000 specimens procured over 20 years. The company acquired the tumor bank, along with properly de-identified clinical information and validated test procedures, as part of a major acquisition of key assets formerly owned by Oncotech.

17 Nov 2010

Stratatech receives SBIR grant to develop anti-infective living human skin substitute

Stratatech Corp., a privately-held regenerative medicine company, today announced that it has been awarded a $3.5 million Fast-Track SBIR grant to expand the development of its anti-infective living human skin substitute.

17 Nov 2010

ALLOZYNE's AZ17 antagonist shows positive data for treatment of autoimmune diseases

ALLOZYNE Inc. announced today positive data from preclinical studies evaluating AZ17 which is a novel bispecific Th17 antagonist that inhibits the differentiation and effector function of human Th17 cells in vivo.

17 Nov 2010

UCSF, Pfizer announce partnership to accelerate translation of biomedical research

UCSF and Pfizer, Inc. have formed a new partnership to accelerate the translation of biomedical research into effective new medications and therapies for patients.

16 Nov 2010

New mechanism breaks drug resistance in ovarian cancer

Drug resistance is a major obstacle in curing ovarian cancer but new research from the Centenary Institute has discovered a treatment that kills ovarian cancer cells in a new way that can break the resistance mechanism.

16 Nov 2010

4SC to present development of resminostat and preclinical drug candidates at EORTC-NCI-AACR symposium

4SC, a drug discovery and development company focused on autoimmune and cancer indications, today announced that it will present four posters and respective abstracts that highlight the development of its lead oncology compound resminostat and several preclinical drug candidates at the 22nd EORTC-NCI-AACR symposium from 16 - 19 November, 2010 in Berlin, Germany.

16 Nov 2010

Infinity announces Phase 1b/2 clinical trial of IPI-926 in patients with metastatic pancreatic cancer

Infinity Pharmaceuticals, Inc. today announced that enrollment is ongoing locally for a Phase 1b/2 clinical trial of IPI-926, Infinity's oral molecule that inhibits Smoothened, a key component of the Hedgehog pathway, in combination with Gemzar (gemicitabine) in patients with previously untreated, metastatic pancreatic cancer.

16 Nov 2010

RNA-based drugs may prevent premature birth: Research

Tiny molecules called microRNAs act together with hormones to control the onset of labor, raising the prospect that RNA-based drugs might be able to prevent premature labor, researchers at UT Southwestern Medical Center have discovered in a preclinical study.

15 Nov 2010

New investigational drug is well tolerated in children with nmCF

PTC Therapeutics, Inc. today announced the publication of data from a Phase 2a clinical trial of ataluren in children with nonsense mutation cystic fibrosis (nmCF) in the American Journal of Respiratory and Critical Care Medicine.

15 Nov 2010

Novel heart attack treatment results presented at premier USA cardiology forum

Regenerative medicine company Mesoblast Limited (ASX:MSB; USADR:MBLTY) has announced that positive preclinical trial results were presented at the American Heart Association’s annual conference in Chicago showing that the company’s proprietary “off-the-shelf” stem cells can be injected simply, safely, and effectively into the coronary arteries after a heart attack to prevent heart failure.

15 Nov 2010

RXi third quarter net loss increases to $4.1 million

RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutic discovery and development, today reported its financial results for the third quarter ended September 30, 2010.

15 Nov 2010

StemCells seeks Swiss authorization to conduct human neural stem cells clinical trial in chronic spinal cord injury

StemCells, Inc. announced today that is has filed an application with Swissmedic, the Swiss regulatory agency for therapeutic products, to conduct a clinical trial in Switzerland of the Company's HuCNS-SC® purified human neural stem cells in chronic spinal cord injury patients. If authorized, the study would enroll patients who are three to 12 months post-injury.

15 Nov 2010

GTx presents preclinical studies of GTx-758 and GTx-230 for treatment of cancer

GTx, Inc. announced the presentation of preclinical studies evaluating GTx-758, a selective estrogen receptor alpha agonist being developed for first line treatment of advanced prostate cancer, and GTx-230, a novel microtubule polymerization inhibitor.

15 Nov 2010

SuperGen to present three abstracts at EORTC-NCI-AACR International Symposium

SuperGen, Inc., a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today announced the acceptance of three abstracts detailing recent work with SuperGen compounds.

15 Nov 2010

Preclinical News and Research

Imec and PEIRA develop platform for in-vitro study of brain tissue

Aeterna Zentaris presents results of orally active compounds with anti-tumor effects at EORTC-NCI-AACR Symposium

New slice-tilting instrument for in-vitro research on brain tissue

Infinity announces enrollment in IPI-926 Phase 1b/2 clinical trial for pancreatic cancer

Alkermes's ALKS 33 drug candidate offers potential treatment for multiple disease indications

Enzon presents data on three investigational mRNA antagonists at EORTC-NCI-AACR Symposium

MRL announces acquisition of world's largest cryo-preserved human cancer tissue bank

Stratatech receives SBIR grant to develop anti-infective living human skin substitute

ALLOZYNE's AZ17 antagonist shows positive data for treatment of autoimmune diseases

UCSF, Pfizer announce partnership to accelerate translation of biomedical research

New mechanism breaks drug resistance in ovarian cancer

4SC to present development of resminostat and preclinical drug candidates at EORTC-NCI-AACR symposium

Infinity announces Phase 1b/2 clinical trial of IPI-926 in patients with metastatic pancreatic cancer

RNA-based drugs may prevent premature birth: Research

New investigational drug is well tolerated in children with nmCF

Novel heart attack treatment results presented at premier USA cardiology forum

RXi third quarter net loss increases to $4.1 million

StemCells seeks Swiss authorization to conduct human neural stem cells clinical trial in chronic spinal cord injury

GTx presents preclinical studies of GTx-758 and GTx-230 for treatment of cancer

SuperGen to present three abstracts at EORTC-NCI-AACR International Symposium

New Approach Methodologies, the 3Rs and Multimodal Imaging in Preclinical Research - eBook eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics